Calamos Wealth Management’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-66,323
Closed -$7.52M 320
2024
Q2
$7.52M Buy
66,323
+1,504
+2% +$190K 0.4% 60
2024
Q1
$8.99M Sell
64,819
-10,999
-15% -$1.38M 0.5% 53
2023
Q4
$9.41M Sell
75,818
-1,781
-2% -$182K 0.59% 50
2023
Q3
$7.24M Buy
77,599
+17,082
+28% +$1.93M 0.55% 49
2023
Q2
$7.78M Sell
60,517
-861
-1% -$104K 0.57% 47
2023
Q1
$7.13M Sell
61,378
-1,955
-3% -$219K 0.56% 52
2022
Q4
$7.17M Buy
63,333
+626
+1% +$68.7K 0.56% 51
2022
Q3
$5.05M Buy
62,707
+20,119
+47% +$1.7M 0.43% 62
2022
Q2
$3.17M Sell
42,588
-1,016
-2% -$92.7K 0.28% 81
2022
Q1
$5.58M Buy
43,604
+568
+1% +$62.1K 0.42% 66
2021
Q4
$5.78M Sell
43,036
-756
-2% -$109K 0.42% 61
2021
Q3
$5.99M Buy
43,792
+484
+1% +$61K 0.48% 55
2021
Q2
$4.62M Sell
43,308
-2,824
-6% -$271K 0.36% 70
2021
Q1
$4.14M Buy
46,132
+42,552
+1,189% +$3.99M 0.34% 74
2020
Q4
$331K Buy
+3,580
New +$320K 0.03% 241

Other funds holding DXCM

Calamos Wealth Management's DXCM Position: Q3 2024 in Review

Calamos Wealth Management sold out of DexCom (DXCM) in Q3 2024, closing a stake of 66,323 shares — an estimated $7.52M sold.

Calamos Wealth Management first reported a position in DXCM in Q4 2020 and held it in 15 quarters. The position peaked at $9.41M in Q4 2023. 890 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

  • Calamos Wealth Management reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
  • Calamos Wealth Management sold 66,323 DexCom shares in Q3 2024, an estimated $7.52M.
  • Calamos Wealth Management first reported a position in DexCom in Q4 2020 and held it in 15 quarters.
  • Calamos Wealth Management's DexCom position peaked at $9.41M in Q4 2023.
  • 890 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on Calamos Wealth Management's 13F filing for Q3 2024, filed 12 Nov 2024.